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Abstract
Down syndrome (DS) consists of a complex phenotype with constant features, such as men-
tal retardation and hypotonia, and variable features, including heart defects and susceptibil-
ity to Alzheimer’s disease, type 2 diabetes, obesity and immune disorders. Overexpression of 
genes mapping to chromosome 21 (Hsa21) is directly or indirectly responsible for pathogene-
sis of DS phenotypic features, as overexpressed Hsa21 genes dysregulate several other genes 
mapping to different chromosomes. Many of these genes are involved in mitochondrial 
function. Recent studies highlight a link between mitochondrial dysfunction, consistently 
observed in DS subjects, and DS phenotype. In this review, we first provide a basic overview 
of mitochondrial alterations in DS in terms of mitochondrial bioenergetics, biogenesis and 
morphology. We then discuss how mitochondrial malfunction may contribute to the patho-
genesis of clinical manifestations and how specific Hsa21 genes may cause the disruption of 
mitochondrial phenotype. Finally, we focus on drugs, which affect mitochondrial function 
and network to propose possible therapeutic approaches aimed at improving and/or pre-
venting various aspects of the DS phenotype. Our working hypothesis is that correcting the 
mitochondrial defect might improve the neurological phenotype and prevent DS-associated 
pathologies, thus providing a better quality of life for DS individuals and their families.
Keywords: Down syndrome, trisomy 21, mitochondrial dysfunction, mitochondrial 
dynamics, Down syndrome/therapy
1. Introduction
Down syndrome (DS) (OMIM 190685), caused by the trisomy of chromosome 21 (TS21), is the 
most common autosomal aneuploidy compatible with postnatal survival with a prevalence of 
© 2018 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1 in 700 newborns. Its phenotype is highly complex showing constant features, such as mental 
retardation, dysmorphic traits and hypotonia, and variable features, including heart defects, 
susceptibility to Alzheimer’s disease (AD), type 2 diabetes, obesity and immune disorders. 
DS is also a risk factor for a number of diseases, such as thyroid dysfunction, leukemia and 
various other congenital malformations. The mechanisms causing the DS phenotype are still 
largely unknown and little progress has been registered so far in the therapeutic approach to 
ameliorate the life of DS subjects.
Overexpression of genes mapping to chromosome 21 (Hsa21) is clearly responsible for patho-
genesis of DS phenotypic features either in a direct or indirect manner, as overexpressed 
Hsa21 genes affect the regulation of several other genes mapping to different chromosomes. 
Many of these genes are involved in oxidative phosphorylation (OXPHOS) and more gener-
ally in the mitochondrial function [1].
As fully described in the following paragraphs, the mitochondrial dysfunction together 
with the disruption of the mitochondrial network might concur to determine DS phenotypic 
traits. This suggests that correcting the mitochondrial defect might affect the severity of DS 
phenotype.
This review provides first a basic overview of mitochondrial alterations in terms of mitochon-
drial bioenergetics, biogenesis and morphology in DS. The latest theories are reported about: 
(i) how mitochondrial malfunction may contribute to the pathogenesis of clinical manifesta-
tions of DS and (ii) how specific Hsa21 genes may be involved in determining the pathogen-
esis of mitochondrial dysfunction in DS. Finally, we focus on drugs that target genes and/or 
pathways involved in mitochondrial function and mitochondrial network to examine poten-
tial therapeutic approaches.
2. Mitochondrial abnormalities in DS
Increasing evidences, widely documented in scientific literature, highlight that there is a link 
between mitochondrial damages and the complex DS phenotype. The downregulation of 
nuclear-encoded mitochondrial genes (NEMGs) is a hallmark of TS21 in human fetal hearts [1] 
and brains [2]. Transcriptome analysis of fetal heart tissues showed that more than 400 genes 
located on chromosomes other than 21 were differentially expressed, either upregulated or 
downregulated, in trisomic versus non-trisomic hearts [1]. Functional class scoring of these 
genes revealed a global downregulation of NEMGs. Together with the downregulation of genes 
involved in mitochondrial pathways, we demonstrated, in trisomic fetal fibroblasts of the same 
subjects, that mitochondria exhibited morphological abnormalities like increased size, irregu-
lar shape and evident breaks, mainly of inner membranes. Mitochondria with concentric and 
longitudinal cristae were significantly more abundant. Stereological analysis demonstrated that 
mean mitochondrial volume was significantly lower in DS cells [3, 4]. All indices of mitochon-
drial respiratory functions were decreased and a significant alteration in the redox homeostasis 
was observed, highlighted by an increased production of reactive oxygen species (ROS) and a 
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higher steady level of intra-mitochondrial Ca2+ [3]. DS fibroblasts also showed a deficit of whole 
energy status as demonstrated by a decrease of basal ATP content and of mitochondrial mem-
brane potential (Figure 1) [4].
Representative confocal microscopy live cell imaging of TMRM fluorescence in euploid and 
trisomic fibroblasts. A significant decrease in fluorescence intensity is observed in trisomic 
samples when compared with euploid ones.
These results were in agreement with different studies that demonstrated a less efficient mito-
chondrial energy production apparatus in fibroblasts from DS subjects due to the impair-
ment of mitochondrial respiratory chain complex I, ATP synthase, ADP/ATP translocator and 
adenylate kinase activities [5, 6].
The protein expression of mitochondrial electron transport enzyme subunits has been found 
decreased in the brain of people affected by DS [7]. Decreased mitochondrial redox activity 
and membrane potential have also been observed both in DS astrocytes [8, 9] and in the brain 
of the Ts1Cje mouse model [10]. In neural progenitor cells (NPCs) isolated from the hippo-
campus of Ts65Dn mice, another widely used model of DS, a severe impairment of mitochon-
drial bioenergetics and biogenesis and reduced NPCs proliferation were demonstrated [11]. 
Furthermore, microarray analysis revealed that numerous pathways were altered in Ts65Dn 
muscle, including pathways involved in ATP biosynthesis [12].
Together with mitochondrial function alterations, a significant disruption of mitochondrial 
dynamics has been observed in trisomic cells. An increased fragmentation of the mitochon-
drial network was demonstrated in primary cultures of TS21 astrocytes and neurons [13] and 
in trisomic fetal fibroblasts [4] (Figure 2). In agreement with the impairment of mitochondrial 
network towards the fragmentation, the expression of MFN2 and OPA1, two fusion-inducing 
genes, was decreased in the same cells.
Figure 1.  A significant decrease of fluorescence intensity demonstrates that membrane potential is reduced in DS fibroblasts.
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Representative images showing that the mitochondrial network is less fragmented in euploid 
fibroblasts than in trisomic ones. Magnifications of intracellular selected details show that 
the number of mitochondria is significantly higher in trisomic cells compared with non-
trisomic cells.
A link between mitophagy and mitochondrial dynamics has been recently demonstrated 
[14, 15], as mitochondrial fusion and fission play a significant role in disease-related pro-
cesses, such as mitophagy and apoptosis. Dysfunctional and damaged mitochondria are 
removed from the mitochondrial network via mitophagy processes. The segregation of 
impaired mitochondria due either to fission or to inhibition of fusion mechanism is hypoth-
esized to be a requirement for this mitophagic degradation [16]. Mitophagy impairments are 
involved in the development of several neurodegenerative diseases [17].
The knowledge of molecular bases of mitochondrial dysfunction is allowing to set-up most 
appropriate therapeutic solutions to counteract it, as more fully described in the following 
paragraphs.
Figure 2. Mitochondrial network is fragmented in DS fibroblasts.
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3. Pathogenesis of mitochondrial dysfunction in DS
3.1. PGC-1α is a key modulator of mitochondrial biogenesis and respiratory 
function
A common denominator of most of the events that affect mitochondrial function is the 
transcriptional coactivator PGC-1α/PPARGC-1α (peroxisome proliferator-activated recep-
tor gamma coactivator 1alpha), a master regulator of mitochondrial activity [4–6]. PGC-1α, 
through the interaction with transcriptional partners, such as NRF1, ERRa, PPARs and YY1, 
promotes mitochondrial biogenesis and regulates mitochondrial respiratory capacity [18, 19]. 
Also these PGC-1α transcriptional partners, as well as many NEMGs, have been found down-
regulated in DS fetal heart tissue [1] and fibroblasts [3]. PGC-1α knockout mice manifest a 
reduction of mitochondrial number and of respiratory capacity in skeletal muscle [18].
PGC-1α transcription and activity are positively regulated by Ca2+ signaling and negatively 
regulated by the Hsa21-coded corepressor NRIP1 (nuclear receptor interacting protein 1) 
[19]. Indeed, PGC-1α has been found hypoexpressed at the transcriptional and protein lev-
els in TS21 fetal fibroblasts, directly correlated with the amount of mtDNA, while NRIP1 
was upregulated [3]. PGC-1α activity was also found decreased in the hippocampus of 
DS patients, as well as in Alzheimer’s, Huntington’s (HD) and Parkinson’s (PD) disease 
patients [20].
3.2. Role of Hsa21 genes in mitochondrial dysfunction
Little is known about the mechanisms by which trisomy 21 causes the abnormal features 
typical of the DS phenotype, apart the knowledge that the dosage imbalance of genes on 
Hsa21 and the resulting dysregulation of genes mapping to different chromosomes share the 
responsibility for molecular dysfunctions in DS.
Hsa21 gene expression was found globally upregulated 1.5-fold in trisomic samples [1, 2], in 
full agreement with a gene-dosage effect. A comprehensive meta-analysis from 45 DS gene 
expression studies [21] identified 77 Hsa21 genes mostly upregulated across all the studies, 
which are likely involved in the DS phenotype. Six of the genes included in this list, namely 
NRIP1, SUMO3, DYRK1A, DSCR1/RCAN1, SOD1 and APP, are directly or indirectly involved 
in mitochondrial function. Other Hsa21 genes not included in the Vilardell’s list, such as ETS-2, 
ITSN1, PKNOX1/PREP1, BACH1 and S100B, were found to be involved in apoptotic events 
and/or to contribute to the regulation of oxidative stress when overexpressed [22]. The dys-
regulation of one or more of these genes, listed in Table 1, might account for mitochondrial 
alterations observed in DS, as discussed below.
3.2.1. NRIP1
We recently demonstrated that NRIP1 overexpression is responsible for decreased respira-
tory efficiency and altered morphology of mitochondria in DS [23]. NRIP1 is a corepressor 
that interacts with nuclear receptors and regulates the expression of genes that control meta-
bolic processes such as energy homeostasis [24–27]. Its activity on mitochondrial pathways is 
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mainly exerted through the repressive control of PGC-1α [19]; the two proteins have mutu-
ally antagonizing roles in NEMG regulation. In neonatal rat cardiomyocytes, it was demon-
strated that overexpressed NRIP1 abrogates PGC-1α-mediated induction of mitochondrial 
membrane potential and mitochondrial biogenesis [25]. Furthermore, at least 1/3 of NEMGs 
upregulated after PGC-1α induction in human osteoblast-like cells [28] were found to be 
NRIP1 targets [23].
To assess that, among the Hsa21 transcription regulators, NRIP1 was indeed the main dys-
regulator of mitochondrial gene expression, the Gene Expression Omnibus (GEO) reposi-
tory (http://www.ncbi.nlm.nih.gov/geo) was screened for gene expression data related to 
the modulation of Hsa21 genes. The functional class scoring of the lists of genes dysreg-
ulated, when Hsa21 genes were individually overexpressed (GSE19836 experiment [29]), 
demonstrated that, among the Hsa21 transcription factors or regulators, only NRIP1 was 
able to affect NEMG regulation with a cluster of 37 NEMGs downregulated after NRIP1 
overexpression [23].
Genes and transcripts Effects on mitochondrial phenotype
NRIP1/RIP140—nuclear receptor interacting 
protein 1
Decreases respiratory efficiency and alters morphology of 
mitochondria
APP—amyloid beta precursor protein Induces mitochondrial oxidative stress and mitochondrial 
dysfunction
SUMO3—small ubiquitin-like modifier 3 Modulates NRIP1 repressive activity and attenuates the 
transcriptional activity of PGC-1α
DYRK1A—dual-specificity tyrosine 
phosphorylation-regulated kinase 1A
Controls PGC-1α via the calcineurin/NFAT pathway
DSCR1/RCAN1—Down Syndrome critical 
region gene 1
Controls PGC-1α via the calcineurin/NFAT pathway and is 
associated with calcium overloading
SOD1—superoxide dismutase 1 Is associated with oxidative stress
ETS-2—V-ETS avian erythroblastosis virus E26 
oncogene homolog 2
Promotes the activation of a mitochondrial death pathway
ITSN1—Intersectin 1 Regulates the mitochondrial apoptotic pathway
PREP1—PBX-regualting protein 1 Inhibits the OXPHOS negatively regulating PGC-1α and 
mitochondrial fusion genes OPA1 and MFN2
BACH1—BTB domain and CNC homolog 1 Contributes to the early increase of oxidative stress in DS through 
the inhibition of the HO-1/BVR-A axis
S100B—S100 calcium-binding protein, beta Overexpression induces ROS formation, activation of stress 
response kinases and increased programmed cell death
hsa-mir-155 Affects mitochondrial biogenesis by targeting TFAM
hsa-let-7c May affect mitochondrial function by targeting ANT1
Table 1. Hsa21 genes and transcripts involved in mitochondrial function.
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We then demonstrated that NRIP1 attenuation by siRNA in DS fibroblasts affected NEMG 
expression, increased PGC-1α expression and counteracted mitochondrial dysfunction in 
terms of ROS production, mitochondrial activity, mitochondrial calcium and ATP content [23].
These findings indicate that the Hsa21 gene NRIP1 strongly contributes to the mitochondrial 
dysfunction observed in DS and suggest that the NRIP1-PGC-1α axis might represent a poten-
tial therapeutic target for restoring altered mitochondrial function in DS.
3.2.2. APP
Mitochondrial abnormalities and a decreased COX activity might also be induced by overpro-
duction of beta-APP [30], although the TS1Cje mouse model, in which APP is not triplicated, 
also shows decreased mitochondrial function and ATP production [10]. Overexpression of 
APP induces mitochondrial oxidative stress and activates the intrinsic apoptotic cascade [31]. 
In addition, amyloid-β fragments, particularly Aβ42, exert direct toxic effects on cells, includ-
ing Ca2+ dysregulation, mitochondrial dysfunction and induction of oxidative stress [32, 33]. 
APP protein has been demonstrated to progressively accumulate within mitochondrial matrix 
leading to increased free radicals and impaired mitochondrial metabolism [34]. In addition, 
APP have been shown to translocate into mitochondria when overexpressed in a human corti-
cal neuronal cell line [35]. APP exerts synergistic effects with other Hsa21 genes [36].
3.2.3. SUMO3
It may affect mitochondrial function by modulating the NRIP1 repressive activity [37]. 
SUMOylation also attenuates the transcriptional activity of PGC-1α, possibly by enhancing 
the interaction between PGC-1α and the corepressor NRIP1 that alters its nuclear distribution 
[38]. SUMO3 overexpression in DS could therefore be responsible for a concurrent improve-
ment of NRIP1 function and decrease of PGC-1α activity.
3.2.4. DYRK1A and DSCR1/RCAN1
The protein products of these genes interact functionally. Their increased dosage coopera-
tively leads to dysregulation of the signaling pathways that are controlled by NFAT family 
of transcription factors, with potential consequences for several organs and systems that are 
affected in DS individuals [39]. The two genes control PGC-1α activity via the calcineurin/
NFAT pathway [40], namely through the binding of NFATc genes to the PGC-1α promoter 
[41]. Calcineurin is involved in the regulation of many cellular processes, including cardiac 
hypertrophy, skeletal-muscle development, synaptic plasticity and T-cell activation [39].
RCAN1, also known as calcipressin, has been found chronically overexpressed in the brain 
of both DS patients and sporadic AD patients [42]. RCAN1 overexpression has been linked 
to oxidative stress and mitochondrial dysfunction [42–45] and is strictly related to calcium 
overloading [46], as it affects mitochondrial permeability transition pore (mPTP) function. 
RCAN1-induced mPTP opening leads to a series of consequences, including Ca2+ retention 
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incapability, massive swelling of mitochondria and rupture of the outer membrane [46]. In 
agreement with these data, deregulation of Ca2+ homeostasis and Ca2+-mediated signaling 
has been described in cells derived from trisomic patients or in murine models of DS [47]. 
Mitochondrial Ca2+ concentration was found significantly higher in fibroblasts from DS feti 
[3], which also show swelled mitochondria with damaged membranes [4].
The overexpression of the brain-specific RCAN1.1S isoform in mice promotes dysregulation 
of dynamin-related protein 1 (DRP1), a protein that promotes mitochondrial fission [48]. 
Accordingly, RCAN1 was found to induce mitochondrial autophagy in cardiomyocytes [49].
3.2.5. SOD1
The redox imbalance in DS has been long attributed to overexpression of Cu/Zn superoxide 
dismutase SOD1, whose levels are approximately 50% greater in cells from DS patients than 
in normal ones [50]. SOD1, the major SOD in mammalian cells, catalyzes the dismutation of 
superoxide radicals to H
2
O
2
 and O
2
 and is an important antioxidant defense system [51].
3.2.6. ETS-2
Studies in transgenic mice showed that ETS-2 overexpression induces apoptosis of thymus, 
spleen and brain cells [52]. Furthermore, ETS-2 promotes the activation of a mitochondrial 
death pathway in DS neurons. Overexpression of ETS-2 induces cytochrome c translocation 
to the cytoplasm and apoptotic features in normal human cortical neurons [53].
3.2.7. ITSN1
This gene regulates the mitochondrial apoptotic pathway in endothelial cells [54].
3.2.8. PKNOX1/PREP1
This gene, which encodes for a homeodomain transcription factor, is involved in embryonic 
development regulating the homeobox protein Pbx activity [55]. DS human fibroblasts that 
express higher levels of PREP1 are more sensitive to genotoxic stress. PREP1 demonstrated to 
regulate mitochondrial oxidative phosphorylation components. It directly binds to the pro-
moter region of genes encoding mitochondrial components [56] and indirectly controls the 
stability of p160 Myb-binding protein, a powerful negative regulator of PGC-1α activity [57]. 
In the muscle of Prep1 ablated mice, Pgc-1α expression was increased with consequent increas-
ing in abundance of mitochondrial OXPHOS proteins and in citrate synthase activity together 
with an improved maximal oxidative capacity. Most important, Prep1 ablation significantly 
increased the abundance of Opa1 and Mfn2, two genes inducing mitochondrial fusion [56]. 
These results suggest that PREP1 negatively regulates OXPHOS and mitochondrial network.
3.2.9. BACH1
This gene is a transcriptional regulator, which acts as hypoxia regulator by binding to antioxi-
dant response elements of DNA thus inhibiting the transcription of specific genes involved 
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in cell stress response, including heme oxygenase-1 (HO-1). HO-1 and its partner, biliverdin 
reductase-A (BVR-A), are upregulated in response to oxidative stress. BACH1 protein was 
found decreased in DS brains, coupled with reduced induction of brain HO-1. This supports 
the hypothesis that the dysregulation of HO-1/BVR-A system contributes to the early increase 
of oxidative stress in DS and provides potential mechanistic pathways involved in the neuro-
degenerative process and AD development [58].
3.2.10. S100B
This gene codes for the b subunit of S100 proteins, a large family of calcium-binding proteins. 
The S100B homodimer is the major form in the mammalian brain. It can stimulate neurite 
extension [59] and plays a role in synaptogenesis [60], dendritic branching [61] and apop-
tosis [62]. S100B protein has long been suggested to be involved in glial cell activation and 
neuroinflammation [63]. Elevated brain S100B expression occurs in various disease states, 
including AD and DS. S100B plays an important role in neuroinflammation and in the regu-
lation and maintenance of the serotonergic nervous system, with a particular focus on the 
hippocampus [64].
In vitro studies of DS fetal human neural precursors (HNP) demonstrated that S100B is 
constitutively overexpressed in these cells and that overexpression leads to increased ROS 
formation, activation of stress response kinases and increased programmed cell death. 
Further  studies demonstrated that DS HNPs adopt more gliocentric progenitor phenotypes, 
if compared with euploid controls,  with a consequent reduction in neuronogenesis [65].
3.3. Hsa21 miRNAs involved in mitochondrial phenotype
Hsa21 encodes several classes of non-coding RNAs, the most enriched being long non-coding 
RNAs, while miRNAs are the less represented [66]. The most recent annotation of miRNA 
database (miRBase, release 21) reports 29 miRNAs mapping to Hsa21. At least two of them, 
miR-155-5p and let-7c-5p, are possibly involved in mitochondrial function.
It was recently reported that the Hsa21 miR-155-5p affects mitochondrial biogenesis by target-
ing the mitochondrial transcription factor A (TFAM) [67], a gene that was found downregu-
lated in trisomic hearts [1]. TFAM is a nuclear-encoded protein that controls the transcription 
and maintenance of mtDNA and therefore mitochondrial biogenesis.
Another Hsa21 miRNA potential candidate for mitochondrial anomalies is let-7c. By bioin-
formatics analysis, it appears to have several targets among genes that were found down-
regulated in trisomic fetal hearts and involved in mitochondrial function. Among these 
targets, SLC25A4/ANT1 [68] appeared as a potential candidate for both mitochondrial 
dysfunction and congenital heart defects in DS. This gene functions as a gated pore that 
translocates ADP and ATP between cytoplasm and mitochondria, regulating the intracellu-
lar energetic balance. Furthermore, its dysregulation has been associated to mitochondrial 
cardiomyopathies [69] and its genetic inactivation results in mtDNA damage and ROS 
increase [8].
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4. How mitochondrial dysfunction might affect DS clinical 
phenotype?
4.1. Muscle hypotonia
DS patients suffer from muscle hypotonia and altered motor coordination. In theTs65Dn mice, 
the ultrastructural analysis of myofibrils showed mitochondrial structural changes [12, 70], 
whereas microarray analysis revealed that pathways involved in ATP biosynthesis, prote-
olysis, glucose and fat metabolism and neuromuscular transmission were dysregulated [12].
Skeletal muscle is particularly vulnerable to oxidative stress. The disruption of mitochondrial 
network towards fragmentation, together with mitochondrial dysfunction, is an essential step 
of the muscular atrophy programme in adult animals [71]. Conversely, inhibition of the mito-
chondrial fission inhibits muscle loss [72]. Furthermore, changes in mitochondrial morphol-
ogy have been implicated in apoptosis as well as in the regulation of muscle metabolism [73].
It is worth noting that patients with DS have features of premature aging [74, 75] and exhibit 
a decrement in muscle strength if compared with euploid subjects, similar to what occurs in 
aged versus young persons [76]. It is, therefore, possible that muscle hypotonia and motor 
dysfunction in DS share some basic mechanisms with the progressive age-related decrease in 
skeletal muscle mass, strength and quality known as sarcopenia [77].
4.2. Intellectual disability and neurodegeneration
Increasing evidences are demonstrating that mitochondrial function is a key actor in the 
events that lead to intellectual disability and neurodegeneration in DS. Development of the 
DS brain is associated with decreased neuronal number and abnormal neuronal differentia-
tion [78]. Patients with DS show higher levels of oxidative stress at all ages and apoptosis 
and generation of ROS are increased in human fetal DS neurons if compared with the gen-
eral population [78, 79]. DS astrocytes and neuronal cultures [8, 9] as well as the brain of the 
Ts1Cje mouse model [10] show a decrease of mitochondrial membrane potential, ATP pro-
duction and an increase of reactive oxygen species [10]. Mitochondrial bioenergetics and bio-
genesis are impaired during neural progenitor cell (NPC) proliferation in Ts65Dn cells [11]. 
Mitochondrial morphology was found consistently altered in TS21 astrocytes and neurons, 
which exhibit increased fragmentation of the mitochondrial network [13]. Mitochondrial 
function, fission-fusion mechanisms, biogenesis and degradation are critical for synaptogen-
esis, Ca2+ buffering, axonal transport and bioenergetics [80]. Functionally and structurally 
damaged mitochondria do not produce sufficient ATP and are more prone in producing pro-
apoptotic factors and ROS [81], which also represent an early stage in neurodegenerative pro-
cess [82]. An increased risk for AD manifests in most of DS individuals starting from 40 years 
of age [83, 84]. The similarity of neurodegenerative processes between DS and Alzheimer 
disease (AD) and the high prevalence of AD in DS patients suggest that AD and DS share 
common brain alterations possibly due to similar molecular pathways involved in the patho-
genesis, such as mitochondrial dysfunction and oxidative stress [85]. Energy depletion and 
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oxidative stress can also induce amyloidogenic changes in AβPP processing [86]. Busciglio 
et al. [9] demonstrated that there is a marked alteration in AβPP processing and Aβ trafficking 
in cortical DS astrocytes and neurons, similar to those induced in normal human astrocytes by 
inhibition of mitochondrial energy metabolism.
It is important to note that neurodegenerative diseases, such as AD, PD and HD, show alter-
ations of mitochondrial function and fusion and/or fission processes very similar to those 
observed in DS [82, 87] as well as a similar dysregulation of mitochondria-related genes most 
of which are target of the NRIP1/PGC-1α axis [23].
4.3. Heart defects
DS is a major cause of congenital heart defects (CHD), mostly derived from endocardial cush-
ion anomalies, such as atrioventricular septal defects, ventricular septal defects and tetralogy 
of Fallot [88, 89].
Transcriptome analysis of human fetal heart tissues from DS subjects has shown a global 
significant downregulation of NEMGs. Genes from all five complexes were downregulated, 
suggesting that the corresponding proteins and enzymatic activities might be reduced and 
that the mitochondrial function could be consequently impaired [1]. When mitochondrial 
phenotype was analyzed in fibroblasts from the same subjects, a more pronounced chronic 
pro-oxidative state was demonstrated in DS fetuses with congenital heart defects if compared 
with feti without cardiopathy [3]. Significant differences in mitochondrial respiration, com-
plex I activity and ROS production were observed, suggesting a relationship between mito-
chondrial function and cardiac phenotype [3]. These alterations might be harbingers of the 
heart defects associated with Hsa21 trisomy, which could be based on elusive mechanisms 
involving genetic variability, environmental factors and/or stochastic events [1].
Searching for a link between heart development and mitochondria, the focus falls on the 
Hsa21 genes DYRK1A and RCAN1, which play a role in the calcineurin/NFAT pathway [40] 
and are believed to affect both mitochondrial activity and morphology during heart devel-
opment [90, 91]. DYRK1A and RCAN1 are involved in regulating the levels of NFATc phos-
phorylation. The calcineurin/NFAT signaling pathway is known to be a critical regulator of 
organogenesis [92] and the NFATc transcription factors are transiently expressed in the endo-
cardial cushions during heart septation [91]. The DSCR1 and DYRK1A genes, both mapping 
on Hsa21 within the critical region for DS, act synergistically to prevent nuclear translocation 
of NFATc transcription factors and may cause their downregulation [40]. Even modest over-
expression of DYRK1A decreases NFATc protein activity and levels and may induce vascular 
and cardiac defects [40]. The inhibition of the mitochondrial activity in Nfatc3−/−Nfatc4−/− car-
diomyocytes [90] suggests that the calcineurin/NFAT pathway affects mitochondrial activity 
during heart development. Nfatc-null mice show phenotypic anomalies that resemble those 
observed in human DS and 65% of Nfatc1–4-null mice have endocardial cushion defects 
[40]. In human DS fetal fibroblasts and hearts, NFATc3 and NFATc4 were found significantly 
downregulated, whereas DYRK1A and RCAN1 were overexpressed possibly due to dosage 
effect [1, 3].
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In addition to congenital heart defects, DS subject may develop ventricular hypertrophy dur-
ing the post-natal life possibly as a result of reduced mitochondrial electron-transport chain 
activity and oxygen consumption. Alterations in mitochondrial function observed in right 
ventricular cardiac hypertrophy are mainly attributed to complex I dysfunction [93]. NRIP1-
dependent repression of mitochondria related genes may be involved in the pathogenesis 
of this defect. The overexpression of this gene in a transgenic mouse demonstrated to cause 
cardiac hypertrophy [94].
Also the Hsa21 miR-155, a known repressor of TFAM gene [67], was uncovered as an inducer 
of pathological cardiomyocyte hypertrophy, suggesting that inhibition of endogenous miR-155 
might have clinical potential to suppress cardiac hypertrophy and heart failure [95]. MiR-155 is 
overexpressed in fetal heart tissue possibly due to dosage effect [68].
4.4. Type 2 diabetes and obesity
Children with DS have an increased risk of developing endocrine disorders such as type 2 
diabetes and obesity [96]. The hypothesis that prominent features of type 2 diabetes and the 
condition of obesity are caused by mitochondrial dysfunction and by an impaired bioenerget-
ics capacity is definitively emerging [97]. Given the important role that mitochondria play for 
bioenergetics support of signal transduction, fat oxidation and substrate transport, an impair-
ment of electron transport chain activity may have particular relevance to the pathogenesis of 
insulin resistance in type 2 diabetes [98]. This hypothesis is substantiated by two evidences: (i) 
a disproportionately large reduction of electron transport chain activity has been observed in 
the subsarcolemmal mitochondrial fraction in type 2 diabetic and obese subjects if compared 
with unaffected volunteers and (ii) mitochondria from human skeletal muscle were found to 
be smaller and to have reduced activity of complex I in both type 2 diabetes and obesity [99].
Interestingly, the Hsa21 corepressor gene NRIP1 and its target PGC-1α play key roles in the 
transcriptional regulation of genes involved in energy homeostasis. The expression and pro-
moter activity of CIDEA, an important regulatory factor in adipose cell function and obesity, 
is repressed by NRIP1 and induced by PGC-1α [100]. These genes are also involved in glucose 
uptake by affecting the regulation of both transcription and subcellular localization of the 
insulin-sensitive glucose transporter GLUT4 [101]. This evidence suggested that NRIP1 might 
be a potential therapeutic target in the treatment of insulin resistance in obese and type 2 
diabetic patients [101]. Accordingly, mice lacking Nrip1 are lean, show resistance to high-fat 
diet-induced obesity and have increased oxygen consumption [102].
Some evidences support the role of an altered mitochondrial dynamics in obesity. It is known 
that obesity in both humans and mice is associated with reduced Mfn2 expression and there-
fore with a defective mitochondrial fusion machinery [103]. Furthermore, an altered proteo-
lytic processing of the GTPase OPA1 in humans is associated with insulin resistance [104].
4.5. Immune disorders
Children with DS demonstrate an increased susceptibility to infections, usually of the upper 
respiratory tract [105–107], and autoimmune disorders, including hypothyroidism [108] and 
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celiac disease [109, 110]. The abnormalities of the immune system associated with DS include 
alteration of B and T-cell number, with marked decrease of naive lymphocytes; abnormal 
thymus functions and development; impaired mitogen-induced T cell proliferation; reduced 
specific antibody responses to immunizations and defects of neutrophil chemotaxis [111, 112]. 
The rates of lymphocyte respiration in the children with DS were found slower than in the 
control group [113].
Important roles of mitochondrial dynamics in the immune system physiopathology have 
been recently demonstrated. The first evidence is that mitochondria transportation during 
lymphocyte migration requires mitochondrial fission [114]. The second is that mitochondrial 
remodeling works as a signaling mechanism that instructs T cell metabolic programming 
[115]. This theory arises from the demonstration that T effector (TE) cells show a fragmented 
network with punctuate mitochondria, whereas T memory (TM) cells show fused networks. 
Accordingly, in transgenic Opa1−/− mice, TM lymphocytes show a decreased survival associ-
ated with altered cristae structure and decreased spare respiratory capacity. In addition, TE 
cells could be shifted to a TM fate depending upon changes of mitochondrial dynamics. These 
data suggest that, by altering cristae morphology, fusion in TM cells configures electron trans-
port chain (ETC) complex associations favoring OXPHOS and fatty acid oxidation, whereas 
fission in TE cells leads to cristae expansion, reducing ETC efficiency and promoting aerobic 
glycolysis [115].
5. Therapeutic approaches to improve mitochondrial function in DS
5.1. Possible therapeutic targets
As mitochondrial dysfunction might concur to determine DS mental retardation and other 
health problems, we might expect that counteracting the mitochondrial defects will improve 
and/or prevent some aspects of the DS phenotype.
The few clinical trials so far undertaken to restore mitochondrial function in DS subjects 
using antioxidants and nutraceutics have yielded either poor or discordant outcomes [116, 
117]. Better results were obtained on learning and memory in the mouse model Ts65Dn using 
pentylenetetrazole, memantine, fluoxetine, lithium, epigallocatechin-3-gallate (EGCG) and 
antioxidants such as vitamin E [118]. Also in this case, the clinical trials have not yielded the 
expected results.
The key role of PGC-1α as a modulator of mitochondrial biogenesis and respiratory function 
suggests that therapeutic approach on mitochondrial dysfunction in DS could be based either 
on PGC-1α activators, which have been tested in mouse models for other disease [119–122], 
or on PPARg agonists, which demonstrated to attenuate mitochondrial dysfunction in AD 
mouse models [123–126].
It is known that PGC-1α activity is mainly controlled by PPARs, AMP-activated kinases 
(AMPKs) and the NAD-dependent deacetylase SIRT1 [127]. Direct phosphorylation by AMPK 
promotes PGC-1α-dependent induction at the PGC-1α promoter level [122], whereas SIRT1 
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stimulates PGC-1α activity through deacetylation, thereby inducing mitochondrial biogenesis 
[119]. Pharmacological activators for these proteins, such as metformin, via AMPK induction, 
and resveratrol, via SIRT1 induction, have been tested in mouse models for neurodegenera-
tive diseases in which mitochondrial alterations play a central role such as AD, Parkinson’s 
disease and Huntington’s disease [120–122].
A comprehensive analysis was performed to evaluate in vitro the effects of potential PGC-1α 
activating drugs [128]. The authors pharmaceutically targeted the PPARs (bezafibrate, rosi-
glitazone), AMPK (AICAR, metformin) and SIRT1 (resveratrol) pathways in HeLa cells, neu-
ronal cells and PGC-1α-deficient MEFs demonstrating tissue-specific effects of these drugs in 
modulating mitochondrial processes and cellular stress programs. All the observed effects 
were clearly dependent on PGC-1α modulation.
5.2. Advances in preclinical and clinical therapeutic approaches
5.2.1. Antioxidants
Most of the clinical trials so far undertaken in DS patients are based on antioxidant nutrients 
or vitamin administration to scavenge oxygen-derived free radicals [129, 130].
A study in which a mixture of antioxidants (selenium, zinc, vitamin A, vitamin E and vitamin C) 
and/or folinic acid was administered as supplementation to children with DS aged under 
7 months for about 18 months provided no evidence to support the use of these supplements 
as this supplementation did not affect oxidative stress [131]. An interesting comment to this 
study was “This is perhaps not surprising because differences between foetuses with Down's 
syndrome and unaffected foetuses can be identified after only 11 weeks gestation, implying 
that by 7 months of age, any damage may already have been done” [132]. Vitamin E adminis-
tration in a recent study did not demonstrate to slow the progression of cognitive deterioration 
in older individuals with DS [133].
Coenzyme Q10 (CoQ10) is a bioactive quinone ubiquitous in the organism, involved in mito-
chondrial bioenergetics, with a known role as a lipophilic antioxidant [134]. CoQ10 supple-mentation to 10 patients with TS21 for 3 months demonstrated that the pro-oxidant state 
in plasma of children with trisomy 21, as assessed by ubiquinol-10:total CoQ10 ratio, may be normalized with ubiquinol-10 supplementation [130]. The authors concluded that further 
studies would be needed to determine whether correction of this oxidant imbalance improves 
clinical outcomes of children with trisomy 21 but no results in this direction have yet been 
communicated.
Overall, these results show that antioxidant supplementation is safe but it does neither 
improve the cognitive performance nor dementia in DS patients.
5.2.2. Melatonin
The antioxidant properties of melatonin induced to study plasma melatonin concentrations 
in a small group of children with DS [135]. Plasma melatonin concentrations were lower in DS 
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subjects than in age-matched controls. The authors concluded that this constituted an added 
oxidative risk to children with DS. Melatonin treatment has demonstrated to induce anti-
oxidant and antiaging effects in the hippocampus of adult Ts65Dn mice [136]. Unfortunately, 
even though this treatment attenuated the oxidative damage and cellular senescence in the 
brain [136], pre-and post-natal melatonin administration in an additional study partially reg-
ulated brain oxidative stress but did not demonstrated to improve cognitive or histological 
alterations in the same DS mouse model [137].
5.2.3. Epigallocatechin-3-gallate (EGCG)
EGCG—a member of a natural polyphenol family—is a mitochondrial-targeted molecule dis-
playing a selective antiapoptotic effect against inducers of mitochondrial oxidative stress in a 
variety of neuronal cell types [138]. EGCG has been found to prevent mitochondrial deteriora-
tion in aged rat brain [139], reduce cerebral amyloidosis [140] and correct amyloid-induced 
mitochondrial dysfunction in a transgenic mice model of Alzheimer disease [141].
EGCG modulates key regulators of mitochondrial metabolism such as Sirt1 activity [142] 
and cAMP levels [143, 144] in addition to being a specific and safe inhibitor of the Hsa21 
gene DYRK1A, a kinase protein involved in brain development and in the control of synap-
tic plasticity [145]. This makes EGCG an interesting candidate drug for the treatment of DS 
phenotype.
A therapeutic benefit on mitochondrial activity by EGCG has been demonstrated in cellular 
and murine model of DS. Indeed EGCG treatment renews the capacity of DS cells to produce 
energy by mitochondrial OXPHOS and to prevent mitochondrial ROS overproduction [146]. 
The treatment of neural progenitor cells, isolated from the hippocampus of Ts65Dn, by EGCG 
reactivates mitochondria bioenergetics and biogenesis and promotes neural progenitor cell 
proliferation [11]. On the other hand, in vivo studies demonstrated that young adults with 
DS treated with EGCG exhibit some cognitive benefits, although these effects disappear with 
time [147]. Furthermore, the treatment carried out in the mouse model Ts65dn in the neonatal 
period rescues numerous trisomy-linked brain alterations. However, even during this critical 
time window for hippocampal development, EGCG does not elicit enduring effects on the 
hippocampal physiology [148].
A further study showed that a temporally specific prenatal EGCG treatment improved some 
craniofacial dysmorphology associated with DS in Ts65Dn embryos and mice. EGCG in 
particular improved neural crest cells (NCC)-related deficits in proliferation and migration 
in vitro in mandibular precursor cells from Ts65Dn E9.5 embryos. In vivo treatment with 
EGCG at E7 and E8, around the time of the developing NCC deficit, appeared to improve 
some of the NCC embryonic dysmorphology in Ts65Dn E9.5 embryos [149]. However, a long-
lasting EGCG treatment at a lower dose (E0–E9) did not have the same corrective effects.
More recently, the same authors demonstrated that a higher dose of EGCG inTs65Dn mice 
and euploid littermates failed to improve cognitive deficits; EGCG also produced several det-
rimental effects on skeleton in both genotypes [150].
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In conclusion, EGCG stimulates mitochondrial biogenesis and promotes oxidative phosphor-
ylation through cAMP/PKA- and sirtuin-dependent mechanism [146], and also, at higher con-
centrations, it promotes apoptosis through mitochondrial damage, membrane depolarization 
and cytochrome c release [151, 152]. All these results suggest that timing and dosage of EGCG 
treatment are important and have to be optimized in treating DS-related phenotypes.
5.2.4. Resveratrol
Resveratrol (RSV), a natural polyphenolic compound found in a wide variety of plant spe-
cies, induces expression of genes involved in mitochondrial biogenesis, oxidative phosphory-
lation and endogenous antioxidant defense by modulation of cell signaling pathways that 
control cell homeostasis. RSV treatment protected mice against diet-induced obesity and 
insulin resistance. This effect was largely explained by an RSV-mediated decrease in PGC-1α 
acetylation and an increase in PGC-1α activity [153]. RSV increased the mean life expectancy 
and maximal lifespan in a mouse model of sporadic and age-related AD. RSV-supplemented 
animals showed increased Sirt1 expression and consequent downregulation of apoptotic pro-
tein p53 in the cortex and hippocampus. Also, p-AMPK in the cortex and total AMPK in the 
hippocampus were increased [153]. Although thousands of research papers have been pub-
lished related to RSV pharmacological activities in many diseases, only one study has been 
performed on the effect of this polyphenol in DS [11]. The authors of the study conclude that 
RSV can sustain and enhance mitochondrial functions by upregulating PGC1α/Sirt1/AMPK 
axis and promote neural precursor proliferation from Ts65Dn. They suggest resveratrol as a 
new drug to be tested in vivo as potential therapeutic tool to promote mitochondrial func-
tions, accelerate neurogenesis and ultimately counteract some of the DS clinical features [11].
5.2.5. Metformin
The effects of the biguanide metformin on mitochondrial function have been investigated in 
human trisomic fibroblasts [4]. Metformin demonstrated to induce both the expression and 
the activity of PGC-1α and to upregulate its target genes NRF-1 and TFAM, thus promoting 
mitochondrial biogenesis. The drug enhanced ATP production in treated cells and improved 
overall mitochondrial activity. Most interestingly, metformin treatment counteracted mito-
chondrial fission observed in trisomic fibroblasts, inducing the formation of a mitochondrial 
network with a branched and elongated tubular morphology (Figure 2) and regulating the 
expression of genes involved in the fission/fusion machinery, namely OPA1 and MFN2 [4].
Metformin has shown to improve cognition in patients with mild cognitive impairment and 
AD [154]. There were no serious adverse events related to its administration.
Metformin is a drug commonly used as a hypoglycemic agent in type 2 diabetes because it 
inactivates gluconeogenesis [155]. Metformin activates AMPK in the liver and muscles, caus-
ing the phosphorylation and the consequent activation of PGC-1α, and upregulates SIRT1 
that in turn activates PGC-1α by deacetylation [155].
Moreover, it has been found that metformin promotes neurogenesis in rodent and human 
neural precursors and enhances spatial memory formation in normal adult mouse [156].
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Metformin is an already registered drug with limited side effects that can be safely admin-
istered during pregnancy and crosses both the placental and blood-brain barrier [157, 158]. 
For these characteristics, it could be immediately introduced in human therapeutic protocols.
6. Conclusions
The study of candidate pathogenic mechanisms in DS is helping scientists to develop more 
appropriate therapeutic solutions for the treatment of this still untreatable genetic disorder.
A long way has been paved in this direction as we have already gained important knowledge 
about the importance of bioenergetics mechanisms in determining the DS phenotype and the 
roles played by Hsa21 genes in this scenario.
The working hypothesis is that counteracting the mitochondrial defect in DS may improve 
the neurological phenotype and prevent DS-associated pathologies, such as Alzheimer’s dis-
ease, type 2 diabetes, obesity and hypertrophic cardiopathy, thus providing a better quality 
of life for DS individuals and their families.
Impaired energy metabolism, defect of mitochondrial enzyme activities and abnormalities of 
mitochondrial respiration are common characteristics of neurodegenerative conditions [20]. 
On these premises, restoring the mitochondrial function could represent also a promising 
strategy to limit the progression of neurodegenerative diseases and even to delay some com-
mon aging processes.
Should any of these drugs, already registered for different purposes, demonstrate to be effec-
tive, they could be immediately introduced in human therapeutic protocols possibly along 
with specific therapies aimed at restoring cognitive functions.
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